Jennison Associates
HAE icon

Jennison Associates’s Haemonetics HAE Stock Holding History

Jennison Associates’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,536
Closed -$1.27M – 589
2026
Q1 		$1.27M Buy
22,536
+10,433
+86% +$679K ﹤0.01% 474
2025
Q4 		$970K Buy
12,103
+1,290
+12% +$86.7K ﹤0.01% 504
2025
Q3 		$527K Buy
+10,813
New +$669K ﹤0.01% 534
2024
Q1 		– Sell
-6,806
Closed -$582K – 606
2023
Q4 		$582K Sell
6,806
-4
-0.1% -$346 ﹤0.01% 556
2023
Q3 		$610K Sell
6,810
-1,786
-21% -$159K ﹤0.01% 521
2023
Q2 		$732K Sell
8,596
-823
-9% -$69.6K ﹤0.01% 521
2023
Q1 		$779K Sell
9,419
-391
-4% -$31.7K ﹤0.01% 517
2022
Q4 		$772K Buy
9,810
+182
+2% +$14.6K ﹤0.01% 529
2022
Q3 		$713K Buy
+9,628
New +$691K ﹤0.01% 545

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
MMA
Mizuho Markets Americas New York $6.37B AUM 47.14% 1-Year Est. Return

Jennison Associates's HAE Position: Q2 2026 in Review

Jennison Associates sold out of Haemonetics (HAE) in Q2 2026, closing a stake of 22,536 shares — an estimated $1.27M sold.

Jennison Associates first reported a position in HAE in Q3 2022 and held it in 9 quarters. The position peaked at $1.27M in Q1 2026. 136 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Jennison Associates reported no remaining Haemonetics position as of Q2 2026 after selling out during the quarter.
  • Jennison Associates sold 22,536 Haemonetics shares in Q2 2026, an estimated $1.27M.
  • Jennison Associates first reported a position in Haemonetics in Q3 2022 and held it in 9 quarters.
  • Jennison Associates's Haemonetics position peaked at $1.27M in Q1 2026.
  • 136 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.